Abstract
BACKGROUND:
Metagenomic next-generation sequencing (mNGS) is a new method that combines high-throughput sequencing and bioinformatics analysis. However, it has not become as popular due to the limited testing equipment and high costs and lack of family awareness with not much relevant intensive care unit (ICU) research data.
OBJECTIVE:
To explore the clinical use and value of metagenomics next-generation sequencing (mNGS) in patients with sepsis in the ICU.
METHODS:
We conducted a retrospective analysis of 102 patients with sepsis admitted to the ICU of Peking University International Hospital from January 2018 to January 2022. Based on whether mNGS was performed, the identified patients were divided into the observation group (
RESULTS:
The testing cycle of mNGS was shorter than that of the conventional culture (30.79
CONCLUSION:
mNGS is useful in the detection of sepsis-causing pathogens in the ICU with the advantages of short testing time and high positive rate. There was no difference in the 28-day outcome between the two groups, which may be related to other confounding factors such as small sample size. Additional studies with extended sample size are needed.
Get full access to this article
View all access options for this article.
